

> 流行病學 and risk factors (CA Cancer J Clin 2018;68:7)


# COLORECTAL CANCER (CRC)

流行病學 and risk factors (_CA Cancer J Clin_ 2018;68:7)

• 4th most common cancer in U.S. men & women; 2nd leading cause of all cancer death

• 90% of cases occur after age 50. ~75% are sporadic.

![](images/00103.jpeg)

• **COX-2** plays a role. ASA rec for 1° prevention if 50–59 y & ≥10% 10-y CRC risk

Screening (_NEJM_ 2017;376:149)

• **Colonoscopy:** preferred; 90% Se for lesions >1 cm. If polyp, re ✔ in 3–5 y. Removal of adenomatous polyps a/w lower CRC mortality (_NEJM_ 2012;366:687)

_Average-risk 病人_: start at age 50 & repeat q10y preferred

↑ _risk 病人_: ⊕ FHx: screen age 40 or 10 y before index dx, then q5y. IBD: 8–10 y after dx, then q1–2y. Suspect familial syndrome: gene counsel, screen 20–25 yo yearly.

• **Sigmoidoscopy:** benefit with 1-time flex-sig (_Lancet_ 2017;389:1299); less Se than colo or CTC

• **CT colonography (CTC):** ~90% Se for lesions ≥1 cm but less if smaller (_NEJM_ 2008;359:1207). If high-risk, Se only 85% for neoplasia ≥6 mm (_JAMA_ 2009;301:2453).

• **Occult blood** (FOBT): use 3-card home testing (Se 24%) yearly

• **DNA:** ↑ Se, ≈ Sp c/w FOBT but less Se than colonoscopy (_NEJM_ 2004;351:2704)

• Combo DNA + Hb immunoassay with ~90% Se & Sp (_NEJM_ 2014;370:1287)

Pathology and genetics (_Cell_ 1990;61:759; _Nature_ 2014;513:382)

• **Adenoma:** ↑ risk of malig. if polyps >2.5 cm, villous, or sessile. Adenomas typically observed ~10 y prior to onset of cancer (both sporadic & familial).

• **Microsatellite stable (MSS) vs. high instability (MSI-H):** latter sign of mismatch repair gene failure, accounts for 15% CRC, presents more often as early stage, ~5% of met dis.

• **Mutations:** _APC_ (~80%); _KRAS_ (~40%); _TP53_ (50–70%); _DCC_, _SMAD4_, _BRAF_ (~15%)

臨床表現

• Distal colon: Δ **bowel habits**, **obstruction**, colicky abdominal pain, **hematochezia**

• Proximal colon: **iron defic. anemia**, dull vague abd pain, liquid stool

• Associated with _Streptococcus bovis_ bacteremia and _Clostridium septicum_ sepsis

Staging and 治療 (_NCCN Clin Pract Guidelines_; version 1.2019)

• TNM staging: **colonoscopy** + **biopsy/polypectomy** + **intraoperative** + **pathologic**

• CT scans of chest and abdomen/pelvis for mets

• Baseline **CEA**: monitor post resection or follow response; _not_ for screening

• **Chemo options** (_Lancet_ 2014;383:1490): 5FU/ & leucovorin (LV) foundation. 5FU/LV + oxaliplatin &/or irinotecan (FOLFOX, FOLFIRI, FOLFOXIRI, resp). Capecitabine oral 5FU prodrug. TAS102 (trifluridine + tipiracil) in progressive disease (_NEJM_ 2015;372:1909).

• **Biologics:** _anti-VEGF_ (bevacizumab) added to chemo ↑ OS in all subsets of mCRC; _anti-EGFR mAb_ (cetuximab or panitumumab) only in unmutated KRAS/NRAS/BRAF (_NEJM_ 2013;369:1023); _multikinase inhibitor_ (regorafenib) generally in chemo (& biologic) refractory setting (_Lancet_ 2013;381:303); anti PD-1 & PD-1 + CTLA-4 in MSI-H met CRC.

![](images/00104.jpeg)
